Process of preparing (1r, 4r, 5s)-4-(2-chloroethyl)-1-((s)-((s)-cyclohex-2-en-1-yl)(hydroxy)methyl)-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione(salinosporamide a; marizomib)
WO2020205483A1
Sphingosine 1 phosphate receptor modulators
WO2020205481A1
Sphingosine 1 phosphate receptor modulators
WO2020219207A1
Sphingosine 1 phosphate receptor modulator
WO2020205478A1
Sphingosine 1 phosphate receptor modulators
US2018282686A1
Salt formulations for the fermentation of marine microorganisms
WO2018208855A1
Sphingosine 1 phosphate receptor agonists for neuroprotection
EP3596470A1
Use of a proteasome inhibitor for the treatment of central nervous system (cns) cancers
US2020131164A1
Dimethylaminoethanol salt of a glp-1 receptor modulator
WO2018064356A1
Compounds and methods for treating lupus
CA3034108A1
Cxcr3 receptor agonists
WO2018033631A1
Morphic forms of marizomib and uses thereof
WO2017060353A1
Methods for treating inflammatory and other diseases and the use of biomarkers as predictors of clinical sensitivity to treatment with apremilast
US2017097360A1
Methods for treating inflammatory and other diseases and the use of biomarkers as predictors of clinical sensitivity to treatment with apremilast
MX2017007494A
Glp-1 receptor modulators.
CN107074820A
The new receptor modulators of GLP 1
MX2014006622A
Carboxylic acid derivatives comprising four cycles acting as glp-1 receptor modulators for therapy of diseases such as diabetes.
